RMD (resmed.com) Market Value to Book Value Ratio

ResMed Corp (RMD) - corporate logo

ResMed Inc. is developing its apnea treatment ecosystem through the implementation of AI and cloud services, while the expansion of its connected device base offsets risks from GLP-1. The company's market-to-book ratio demonstrates a gap between market expectations and tangible assets, where the 5.52 level records fresh values. Dominance in the CPAP therapy niche and an aging population ensure sustainable margin growth.

RMD - ResMed Corporation Market-to-Book Ratio over the range 07/04/2022 - 10/27/2026
Manufactured products of ResMed Inc

This indicator measures the market value premium over the book value of net assets, determining the extent to which investors have overvalued the capital. By analyzing the current market capitalization relative to the book value, one can assess whether the AirView digital ecosystem and high customer switching costs for ResMed Inc. (RMD) justify market optimism and create a sustainable foundation for long-term growth.

Competitor analysis

Boston Scientific - Market Value to Book Value Ratio|EW (edwards.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio Insulet PODD|Market Capitalization to Net Assets Zimmer Biomet|CooperVision - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Align Corp (ALGN)|Globus Medical, Inc. - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio TransMedics Organ Care System TMDX|Market Capitalization to Book Value Ratio ATEC (Alphatec)|AORT - Market Capitalization to Book Value|ENOV: Market Capitalization to Book Value Ratio|IART (Integra LifeSciences Inc.) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Establishment Labs|Market Value to Book Value Ratio betabionics.com|IRMD (IRADIMED) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Embecta Corp EMBC|Tandem Diabetes (TNDM) - Market Cap to Net Assets Ratio|Market Capitalization to Net Assets Axogen Surgical AXGN|SIBN (SI-BONE, Inc.) - Market Capitalization to Book Value Ratio|OFIX - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Bioventus|Capitalization to Book Value Ratio OrthoPediatrics|TMCI - Market Cap to Net Assets Ratio|Market Value to Book Value SRTA|Market Value to Book Value Ratio CARL (Carlsmed Inc)|Market Cap to Net Assets Ratio rxsight.com (RXST)|CLPT: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Stereotaxis Inc STXS|NeuroStar (STIM) - Market Capitalization to Book Value Ratio|SGHT - Capitalization to Book Value Ratio|Orchestra BioMed - Market Capitalization to Book Value Ratio|Anika Therapeutics, Inc. (ANIK) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio NSPR|Market Cap to Net Assets Ratio Jin Medical International Ltd|Market Capitalization to Book Value Ratio VANI|Market Capitalization to Book Value Ratio XTNT (xtantmedical.com)|Market Value to Book Value Ratio NeuroOne Medical Technologies NMTC|MODD - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Myomo (MYO)|COCH - Market Value to Book Value|Market Capitalization to Book Value Ratio VVOS|NVNO (enVVeno Corp) - Market-to-Book Ratio|Sintx Technologies Inc - Market Value to Book Value Ratio|Market Value to Equity Ratio tenonmed.com (TNON)|Market Cap to Net Assets Ratio LFWD|Market Capitalization to Book Value Ratio autonomix.com (AMIX)|Market Capitalization to Book Value Ratio IVF|Bone Biologics Inc - Market Capitalization to Book Value|Market Value to Book Value Ratio Axonics, Inc.|BIOL: Market Capitalization to Net Assets|DYNT (dynatronics.com) - Market Value to Book Value Ratio|Paragon 28 (FNA) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio INVO (INVO Bioscience Inc.)